The chemokine receptor CXCR4 is an important G protein-coupled receptor. Signaling via CXCL12 regulates a number of important biologic processes, including immune responses, organogenesis, or hematopoiesis. Dysregulation of CXCR4 signaling is associated with a variety of diseases, such as cancer development and metastasis, immunodeficiencies, or chronic inflammation. Here, we review our findings on endogenous peptide inhibitor of CXCR4 as a novel antagonist of CXCR4. This peptide is a 16-residue fragment of human serum albumin and was isolated as an inhibitor of CXCR4-tropic human immunodeficiency virus type 1 from a blood-derived peptide library. Endogenous peptide inhibitor of CXCR4 binds the second extracellular loop of CXCR4, thereby preventing engagement of CXCL12 and antagonizing the receptor. Consequently, endogenous peptide inhibitor of CXCR4 inhibits CXCL12-mediated migration of CXCR4-expressing cells in vitro, mobilizes hematopoietic stem cells, and suppresses inflammatory responses in vivo. We discuss the generation of endogenous peptide inhibitor of CXCR4, its relevance as biomarker for disease, and its role in human immunodeficiency virus/acquired immunodeficiency syndrome pathogenesis and cancer. Furthermore, we discuss why optimized endogenous peptide inhibitor of CXCR4 derivatives might have advantages over other CXCR4 antagonists.
Introduction
CXCR4 is a GPCR with CXCL12 as the sole published chemokine ligand [1, 2] . CXCR4 is expressed by most cells of the hematopoietic and central nervous systems [3, 4] . CXCR4-CXCL12 signaling regulates multiple developmental and physiologic processes, including organogenesis [5] , stem cell homing [6] [7] [8] , or migration of immune cells [9, 10] . Deregulation of CXCR4-CXCL12 signaling is associated with multiple diseases, including various types of cancers, pulmonary fibrosis, inflammation, and immunodeficiencies [11] [12] [13] [14] [15] . In addition, CXCR4 also serves as a major coreceptor for HIV-1 entry into target cells [1] [2] [3] . Thus, CXCR4 represents a promising drug target [15, 16] . However, only AMD3100 (plerixafor) has been approved as CXCR4 antagonist by the U.S. Food and Drug Administration and only for stem cell mobilization in combination with G-CSF in patients with non-Hodgkin lymphoma and multiple myeloma [17] . Several clinical trials concerning the use of CXCR4 antagonists for the treatment of various disorders are ongoing ( Table 1) .
ISOLATION OF AN HIV-INHIBITORY ALBUMIN FRAGMENT FROM HEMOFILTRATE
We previously have used peptide libraries derived from human body fluids as source for the identification of novel peptide inhibitors [18] [19] [20] and enhancers [21, 22] of HIV-1 infection [23] . EPI-X4 was discovered by screening a peptide library generated from 10,000 L of hemofiltrate, an aqueous waste product obtained during dialysis of patients with renal disease [24] . This library consists of 350 fractions containing all bloodderived peptides and small proteins with a molecular weight below 30 kDa in a lyophilized and highly concentrated form [25, 26] . Screening these fractions for inhibitors of CXCR4-tropic HIV-1 in a cell-based infection assay resulted in the identification of 3 neighboring fractions that suppressed infection. Further rounds of chromatographic purification and antiviral assays allowed us to purify a bioactive peptide with a molecular mass of 1830 Da and the sequence LVRYTKKVPQVSTPTL. This 16-mer peptide corresponds to residues 408-423 of HSA, the most abundant protein in serum with reference concentrations between 34 and 54 mg/ml, which is also present in high quantities in the extravascular space [27] . Serum albumin has a molecular mass of 65-67 kDa and is produced by the liver. Its main function is to regulate the oncotic pressure to maintain the proper distribution of body fluids between the intravascular compartment and body tissues [27] . Furthermore, it acts as a nonspecific vehicle for a variety of endogenous and exogenous compounds, including steroid hormones, fatty acids, and drugs.
EPI-X4 IS AN ENDOGENOUS ANTAGONIST AND INVERSE AGONIST OF CXCR4
Synthesized EPI-X4 specifically inhibited CXCR4-but not CCR5-tropic HIV-1, suggesting that the albumin fragment is directly interacting with CXCR4 [24] . Indeed, EPI-X4 binds to a region close to the extracellular loop 2 of the receptor, which overlaps with the binding site of plerixafor. Interestingly, EPI-X4 does not act as agonist but competes with CXCL12 for binding to CXCR4, resulting in receptor antagonism. Furthermore, EPI-X4 reduces the basal signaling activity of CXCR4 (in the absence of CXCL12). Thus, EPI-X4 is not only an antagonist but also an inverse agonist of CXCR4. The biologic consequences of suppressing the constitutive activity of CXCR4 by EPI-X4 remain to be addressed. However, the inverse agonist activity of EPI-X4 could be of advantage in the treatment of diseases associated with hyperactivated CXCR4, such as the WHIM syndrome [14] or Waldenström macroglobulinemia [28] . In these rare diseases, mutations in the cytoplasmic tail of CXCR4 result in impaired receptor desensitization and internalization and lead to enhanced signaling activity. Thus, abrogating both, CXCL12-dependent and -independent signaling by a compound with antagonist and inverse agonist activity could be advantageous over treatments with classic antagonists that do not affect constitutive signaling. Furthermore, the interaction with CXCR4 is highly specific because EPI-X4 does not interfere with signaling of other tested GPCRs, including CXCR7. Thus, EPI-X4 is a highly specific, novel, endogenous antagonist and inverse agonist of CXCR4 [24] . In agreement with its CXCR4 antagonizing activity, EPI-X4 prevented CXCL12-induced receptor internalization and inhibited migration of immortalized T cells, tumor cells, and HSCs toward CXCL12 [24] . Expression of CXCL12 by bone marrow stromal cells provides a key retention signal for CXCR4-expressing HSCs and neutrophils [29, 30] . Intraperitoneal injection of EPI-X4 into mice resulted in a transient mobilization of HSCs and neutrophils into the periphery [24] . Furthermore, EPI-X4 had anti-inflammatory effects in a mouse model of acute allergic airway hypereosinophilia [24, 31] . Taken together, these data suggest that EPI-X4 or derivatives thereof might have therapeutic potential for the treatment CXCR4-linked diseases.
DEVELOPMENT OF AN EPI-X4 SPECIFIC SANDWICH ELISA
To study the generation, degradation, and physiologic role of EPI-X4, we established a highly sensitive sandwich ELISA [32] . In brief, antibodies from 2 different species were raised against the N-and C-terminal halves of EPI-X4 by immunization of rabbits (408-415) and guinea pigs (416-423). To achieve maximal specificity for EPI-X4, both antisera were depleted from antibodies that recognize N-and C-terminal truncated variants of EPI-X4. The resulting antibodies were then used as coating and detection antibodies. The ELISA has a linear range between ;0.1 and 5.0 ng/ml, a quantification limit of ;0.5 ng/ml, and a limit of detection at ;0.15 ng/ml. We did not observe any crossreactivity with EPI-X4 length variants or full-length albumin. Importantly, the ELISA also detects EPI-X4 orthologous in mice, rats, and macaques, allowing study of the role of this novel CXCR4 antagonist in respective animal models [32] .
GENERATION OF EPI-X4 FROM ALBUMIN
The sequence corresponding to EPI-X4 (408-423) is partially accessible at the surface of the heart-shaped albumin molecule [24] . Alignment of albumin sequences from different mammalian species revealed variations at only 3 amino acid positions of the EPI-X4 regions, with highly conserved putative protease restriction sites at its N and C termini. Using the EPI-X4 ELISA, we found that aspartic proteases cathepsin D and E release the CXCR4-antagonizing peptide from the albumin precursor under acidic conditions [24] . Thus, EPI-X4 is generated through limited proteolysis of albumin by enzymes that are present in lysosomes of virtually all cell types [33, 34] , suggesting that the CXCR4 antagonist may be produced intracellularly. EPI-X4 may then be released, for example, during pyroptosis, a form of programmed cell death associated with antimicrobial responses during inflammation [35, 36] . Cathepsin D and E are also found in specialized secretory granules of leukocytes and may be released into the extracellular space in response to immunologic stimuli to generate EPI-X4 in the extracellular space [37, 38] . Indeed, we found that EPI-X4 is generated de novo in acidified human plasma or serum at physiologically relevant levels in the microgram per milliliter range [24] . Again, aspartic proteases were responsible for the generation of the CXCR4 antagonist as pepstatin A, a specific inhibitor of these enzymes, blocked this process [24] . Thus, the prerequisites for the rapid generation of EPI-X4, that is, the albumin precursor and cathepsin D or E, are given essentially everywhere in the human body, and its generation is triggered by low pH conditions, which represent a hallmark of inflammatory and tumor environments [39] [40] [41] [42] as well as a danger signal in innate immunity [43] . At sites of inflammation and immune activity, EPI-X4 is ideally positioned to limit local inflammatory responses. Moreover, acidic pH values and high levels of cathepsins are characteristic for malignant tumors [44, 45] .
STRUCTURE AND REGULATION OF EPI-X4
Nuclear magnetic resonance spectroscopy revealed that the16-mer peptide adopts a "lasso-like" structure [24] . Residues Leu-1, Tyr-4, and Pro-9 interact to form a "ring," whereas V11-L16 form the "tail." EPI-X4 has 2 highly distinct surfaces: one is highly positively charged and most likely responsible for receptor interaction, and the other is strongly hydrophobic. Alteration of the hydrophobic nucleus by elimination of L1 abrogates ring formation and loss of CXCR4 binding activity. Interestingly, this is most likely also the mechanism by which EPI-X4 activity is regulated in vivo. The half-life of EPI-X4 in plasma of healthy human individuals is ;17 min [24] , which is similar for most other natural peptides. Degradation of EPI-X4 is inhibited by L-leucinethiol, an inhibitor of leucine aminopeptidases. This class of serum enzymes preferentially catalyzes the hydrolysis of leucine residues at the N terminus of the peptides [46] . Indeed, mass spectrometry analysis of plasma incubated with EPI-X4 (408-423) confirmed the presence of the inactive 409-423 sequence. Thus, EPI-X4 is likely generated locally under acidic conditions and is inactivated at neutral pH by leucine aminopeptidases (Fig. 1) .
OPTIMIZED EPI-X4 DERIVATIVES AS NOVEL THERAPEUTICS FOR CXCR4-LINKED DISEASES
EPI-X4 represents an interesting lead for further clinical development. It is not immunogenic and, in contrast to plerixafor, does not bind CXCR7; it reduces basal signaling activity of CXCR4, and does not exert mitochondrial cytotoxicity [24] . However, EPI-X4 concentrations that are required to antagonize CXCR4 are in the micromolar range and thus too high for therapeutic intervention. A structure-activity relationship study allowed us to improve the CXCR4-antagonizing activity by 2 orders of magnitude [24] . For example, we found that truncations of the "tail" in EPI-X4 did not affect anti-CXCR4 activity. Further, amino acid substitutions in the backbone of the derivative 408-419 allowed us to generate EPI-X4 derivatives that inhibited CXCR4-tropic HIV-1 infection and suppressed leukemia cell migration toward CXCL12 with activities in the nanomolar range [24] . It is noteworthy that these derivatives remained active even after 24 h of incubation in serum and blocked CXCL12-induced actin polymerization and HSC migration as efficiently as plerixafor. The therapeutic potential of these EPI-X4 derivatives is currently being tested in various mouse models of CXCR4-associated diseases, such as in xenograft models of pancreatic cancer, osteosarcoma, and leukemia.
EPI-X4 AS BIOMARKER?
As expected for an inhibitor of the pivotal CXCR4 receptor, EPI-X4 levels in plasma and urine of healthy individuals were generally below the detection limit (;0.1 ng/ml). However, concentrations of EPI-X4 (in micrograms per milliliter) were detected in the urine of patients with renal failure, and urinary levels of the CXCR4 antagonist correlated with the glomerular filtration rate in these individuals [24] . It is noteworthy that EPI-X4 was not generated after urination, and its concentrations remained stable in urine over several days [32] . Thus, EPI-X4 in these samples was originally generated in vivo, and its urinary levels may represent a novel diagnostic and/or prognostic marker for renal inflammation and/or chronic kidney disease. The appearance of EPI-X4 seems to be affected by initial changes in proteolytic activity associated with inflammatory processes at the onset of renal disease [47, 48] . However, the CXCR4/CXCL12 signaling axis preserves microvascular integrity and renal function in chronic kidney disease [8] , and elevated levels of CXCL12 predict myocardial infarction and death in these patients [49] . Thus, increased endogenous levels of EPI-X4 may represent a specific response against overshooting CXCR4
signaling. Moreover, these observations suggest that EPI-X4 has therapeutic potential in chronic kidney disease and associated disorders.
EPI-X4 AND ITS ROLE IN HIV/AIDS
A rapid decline in T cell counts and the progression to AIDS is often associated with a switch from R5-tropic to X4-tropic virus in 50% of all patients [50] [51] [52] . Initially, EPI-X4 was identified by screening a hemofiltrate-derived peptide library for novel inhibitors of X4-tropic HIV-1 [24] . We have not detected EPI-X4 in plasma of HIV-1-infected individuals with acute or chronic infection, or even at late-stage disease, suggesting that EPI-X4 does not control X4-tropic HIV-1. However, recent studies demonstrated that HIV-1 causes pyroptosis that drives CD4 T cell depletion and inflammation in lymphatic tissues, the main sites for viral replication in vivo [53] . During pyroptosis, lysosomes containing the EPI-X4-generating protease cathepsin D fuse with the cell surface and release their content into the extracellular space where albumin is present. This could result in the local generation of EPI-X4, where it may suppress X4-tropic HIV-1. Whether this is, indeed, the case and whether EPI-X4 is detectable in HIV-1-infected, long-term nonprogressors are being addressed in ongoing studies.
EPI-X4 AND CXCR4 INHIBITION AGAINST CANCER STEM CELL-DRIVEN METASTASIS
CXCR4 is highly expressed in most human cancers and is intricately linked to tumor growth, metastasis, and therapy resistance [54] [55] [56] . As a consequence, CXCR4 expression correlates with survival, metastatic activity, and tumor relapse in various solid tumors (e.g., colorectal [57] and pancreatic cancers [58] ), predicting poor prognosis and response to therapy of patients with cancer. There is increasing evidence that tumor cells are highly heterogeneous and contain a population of CSCs [59] that have self-renewal capacity, can generate the heterogeneous cells of the original tumor, and are exclusively tumorigenic in secondary recipients in vivo. We have identified a metastatic subpopulation of pancreatic CSCs, which is characterized by the expression of CD133 and CXCR4, which can be detected in the invasive front of the tumor as well as in the bloodstream, and which are exclusively able to generate distant organ metastasis [60] . Migration of these cells to metastatic organ sites is mediated by the expression of the CXCR4-CXCL12 axis. Interestingly, depletion of these cells or treatment with CXCR4 inhibitors, such as the small-molecule inhibitor AMD3100, or antagonizing antibodies completely abrogated their metastatic potential. Although the connection between CXCR4 expression and CSCdriven metastasis seems to be particularly strong in pancreatic cancer, CXCR4 has also been identified as key in metastasis of other epithelial cancer stem cells, such as breast, colorectal, and lung cancer [13. 61, 62] . The great relevance of CXCR4 in mediating metastatic activity in epithelial cancers strongly suggests the development of strategies for its inhibition. The discovery of EPI-X4 as a highly specific inhibitor is a great step in this direction even though further optimization may be necessary. In particular, it will be important to determine the long-term toxicity of EPI-X4 (or its improved derivatives) because inhibiting CXCR4 on cancer cells may also affect biologic function of CXCR4 expressed on other cells, resulting in offtarget effects.
CONCLUDING REMARKS
The CXCR4-CXCL12 signaling axis has a pivotal role in numerous biologic processes, such as organ development, hematopoiesis, vascularization, cell and tissue renewal, hematopoietic stem cell retention, and inflammation and immune control. Many of these processes may involve local pH changes affecting the generation of EPI-X4 and, consequently, CXCR4 signaling activity. Thus, our identification of an endogenous CXCR4 antagonist (and inverse agonist) in humans has implications beyond HIV/AIDS and offers exciting possibilities for future research. For example, it would be intriguing to study the role of EPI-X4 in embryogenesis and organogenesis or CXCR4-linked autoimmune diseases, such as rheumatoid arthritis, systemic lupus erythematosus, or multiple sclerosis. Moreover, EPI-X4 is the first endogenous antagonist of a GPCR generated by proteolytic processing of a highly abundant protein under acidic conditions. This mechanism represents a novel concept in the regulation of GPCRs and adds to the growing evidence that local extracellular acidosis has a key role in the regulation of inflammatory immune responses. This concept in regulation of CXCR4 signaling is conserved from mice to men, and it will be interesting to determine whether other GPCRs are regulated by similar means. Figure 1 . EPI-X4 is generated from serum albumin under acidic conditions by cathepsin D or E. These aspartic proteases are naturally present in blood or can be released from cells by lysosomal exocytosis or pyroptosis. EPI-X4 is inactivated by leucyl aminopeptidases, which that remove the N-terminal leucine, which is essential for CXCR4 binding. EPI-X4 may serve as diagnostic marker for chronic kidney disease or GvHD. EPI-X4 binds CXCR4, thereby inhibiting X4-tropic HIV-1 infection. Furthermore, EPI-X4 antagonizes the receptor by preventing the interaction with the CXCR4 agonist CXCL12. Moreover, EPI-X4 has inverse agonist activity. The biological and pathophysiological roles of EPI-X4 in health and disease remain to be clarified.
